Recombinant human thyroid-stimulating hormone: Initial bioactivity assessment using human fetal thyroid cells

Gerold K. Huber, Po Fong, Erlinda S. Concepcion, Terry F. Davies

Research output: Contribution to journalArticlepeer-review

50 Scopus citations

Abstract

We have assessed the bioactivity of newly available recombinant human TSH (rec-hTSH) using human fetal thyroid cells, with the longer term aim of assessing its use for clinical applications. Rec-hTSH caused a consistent and dose-related increase in thyroid monolayer cell cAMP release and human thyroglobulin (hTg) secretion, confirming its bioactivity. Repetitive studies (n = 5) allowed us to derive an estimated biopotency for the rec-hTSH preparation examined of 5.6 IU/ mg compared to 10 IU/mg for commercially available bovine TSH for human use. The rec-hTSH had a bioimmune ratio of 0.55, similar to that of purified pituitary hTSH standards. Furthermore, rec-hTSH induced thyroid epithelial cell growth, as evidenced by a decrease in thyroid cell doubling time from 54 ± 2.1 to 31 ± 1.7 h (P < 0.005). Hence, rec-hTSH is a potent glycoprotein hormone preparation when measured in a homologous human thyroid cell culture system. Rec-hTSH could serve as a future definitive International Standard and has the potential for a useful diagnostic and therapeutic reagent.

Original languageEnglish
Pages (from-to)1328-1331
Number of pages4
JournalJournal of Clinical Endocrinology and Metabolism
Volume72
Issue number6
StatePublished - Jun 1991

Fingerprint

Dive into the research topics of 'Recombinant human thyroid-stimulating hormone: Initial bioactivity assessment using human fetal thyroid cells'. Together they form a unique fingerprint.

Cite this